ReviewMicrobiology and molecular biology reviews : MMBR2025
Recent developments in
Review in Microbiology and molecular biology reviews : MMBR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- HosA-mediated epigenetic regulation of growth, virulence, and secondary metabolism inVirulence · 2026Article
- Identification and characterization of non-canonical azole antifungal resistance pathways inmBio · 2026Article
- The power of ten: report from the 10th American Society for Microbiology Conference on Biofilms.Journal of bacteriology · 2026Article
- Antifungal Susceptibility andMicroorganisms · 2026Article
- The Janus Face ofVeterinary sciences · 2026Review
- Article
- Article
- Investigation of chitinase B1 inhibitors targeting the cell wall biosynthetic machinery in Aspergillus fumigatus through integrated molecular dynamics and QM/MM.Folia microbiologica · 2026Article
- RTA-like proteins regulate azole susceptibility by affecting the expression of the oxidoreductase gene oxrA in Aspergillus fumigatus.BMC microbiology · 2026Article
- Geographically structured genotypes and resistance clustering in Aspergillus fumigatus.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Functional and molecular characterization ofJournal of medical microbiology · 2026Article
- Article
- Novel Genetic Diversity and Geographic Structures ofMicroorganisms · 2026Article
- Electrophoretic Mobility Shift Assay in Aspergillus fumigatus.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Nebulized Liposomal Amphotericin B as an Alternative Therapy for anCase reports in infectious diseases · 2026Article
- Emergence, function, and therapeutic strategies to target the PD-1/PD-L1 immune checkpoint during pathogenic fungal infections.Virulence · 2025Review
- Human immunity to fungal infections.The Journal of experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
SUMMARYAdvances in modern medical therapies for many previously intractable human diseases have improved patient outcomes. However, successful disease treatment outcomes are often prevented due to invasive fungal infections caused by the environmental mold
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.